constantly replenish the supply of potential blockbusters requires a consistent and dedicated approach to drug R&D. However no longer is inhouse research expertise sufficient. 2 Chart 1 Decreased R&D Productivity (source: FDA - PhRMA 2007) Pharma R&D Investments (Billion USD) 120 New medicines Approved by FDA 60 100 50 80 40 60 30 40 20 20 10 0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 YEAR 0 To fill this pipeline gap‚ pharmaceutical
Premium Net present value Discounted cash flow Cash flow
PHARMA-SAYA INNOVATIVE SOLUTIONS‚ INC. Bringing better smiles that build better lives 259 CEU Bldg.‚ Sen. Gil Puyat Ave.‚ Makati City Phils. OUR MOTTO Bringing better smiles that build better lives. OUR MISSION-VISION STATEMENT PSIS is a Philippine company that values one of the most cognizant traits of the Filipino men‚ being gleeful‚ where the connotation that the SMILE is the most powerful weapon and shield of the Filipino started. The company is dedicated to bring better
Free Metro Manila Manila Toothpaste
REPORT 2009-10 Torrent Pharmaceuticals Limited 2 N TE CO N TS Corporate Information 02 Notice 03 Directors’ Report 06 Report on Corporate Governance 14 Auditors’ Report 24 Audited Financial Statements 28 Management Discussion and Analysis 55 Consolidated Financial Statements 66 37th ANNUAL REPORT 2009-10 3 CORPORATE INFORMATION DIRECTORS Sudhir Mehta Chairman REGISTERED OFFICE Torrent House‚ Markand Bhatt S. H. Bhojani Dr. Prasanna Chandra Kiran Karnik Sanjay Lalbhai
Premium Board of directors Corporate governance
4.1 INTRODUCTION GSK Bangladesh Limited has been an active part of the pharmaceutical scenario of Bangladesh for a long time now. In Bangladesh‚ its functions are surrounded by 3 basic categories of pharmaceutical products. These are: a) Locally manufactured pharmaceutical products like Ventolin‚ Berin‚ Kefdrin‚ Amoxil‚ Dermovate‚ Zantac‚ Lamictal etc. b) Imported pharmaceutical products like Alkeran‚ Leukeran‚ Seretide etc. c) Vaccines like Engerix-B‚ Havrix‚ Hiberix‚ Varilrix etc
Premium Generally Accepted Accounting Principles Balance sheet Financial ratios
combined well with SB’s leaderships in genomics. SB had an existing pipeline of 4 promising drugs in final stages of developments. This was attractive to Glaxo Wellcome who relied heavily on its blockbuster drug Zantac. Performance improvement GSK invested heavily on
Premium
SWOT ANALYSIS Strength- Vigpuff is comparatively harmless than the nicotine counter parts. It can also work as a mouth freshener and will not give the users the bad smell after smoking. It contains all herbal ingredients. Vigpuff is one of its kind new development with caffeine as a main ingredient. The company provides a wide range of products available( variation available)‚ different packaging size The packaging is done keeping in mind ease to carry. Provides smoke for user who do
Free Smoking Nicotine Tobacco smoking
Case study C: GSK‚ a merger too far? 1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance‚ companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France‚ with less demand in new technologies. 2) The very selective anglo-saxon
Premium Pharmacology Generic drug Pharmaceutical industry
Bio Pharma Case Analysis Question 1 How should BioPharma have used its production network in 2009? Should any of the plants have been idled? What is the annual cost of your proposal‚ including import duties? As Landgraf’s objective is to design a more cost-effective network (cost minimization problem subject to various capacity constraints)‚ the following production network in 2009 should have been used by BioPharma: *All numbers below are in millions *Total Transportation Cost=SUMPRODUCT
Premium Costs Total cost Variable cost
Financial statements P102–P191 Shareholder information P192–P212 Business review 2010 Performance overview Research and development Pipeline summary Products‚ competition and intellectual property Regulation Manufacturing and supply World market GSK sales performance Segment reviews Responsible business Financial review 2010 Financial position and resources Financial review 2009 Risk factors Governance and remuneration Our Board Our Corporate Executive Team Governance and policy Dialogue with shareholders
Premium Vaccine Rate of return Clinical trial
01.Retern on capital employed (ROCE) (Return/Capital employed) × 100 2007 2008 2009 Return 654420059 963775308 1156895419 Capital employed 2941937693 13932986985 13512352515 ROCE 5.85% 4.99% 8.56% Table: ROCE 02.Return on shareholders’ fund (ROSF) {Net profit for the period/(Share capital+Reserve)} 2007 2008 2009 Net profit for the period 3597024812 4010167059 4868256915 Share capital+Reserve 1932104953 1554528420 1806443640 ROSF 1.86 2.58 2.69 Table: ROSF
Premium Financial ratios Generally Accepted Accounting Principles Financial ratio